WAVEMAN · COMPANY

ADAPY · Adaptimmune Therapeutics Plc

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ADAPY

Name: Adaptimmune Therapeutics PLC (ADAPY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Adaptimmune Therapeutics PLC

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001621227

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+195.3%

XBRL, annual

NET MARGIN

-39.8%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

+195.3% year over year

more than 89% of Pharma & Biotech

MARGIN

-39.8% net margin

below 55% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

0.1% of shares outstanding short · 1.7 days to cover · settled 2026-07-31

below 88% of Pharma & Biotech

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

Every figure on this page is a federal filing, dated the day it became public — so you can test what was knowable, not what is known now.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Adaptimmune Therapeutics PLC in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Rawcliffe Adrian

Chief Executive Officer

SELL

2021-09-01

2,782.0

$14.5K

1 TRANSACTION ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Executive pay vs shareholder return · Adrian Rawcliffe

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2023

$2.8M

$1.2M

-34%

+15%

2022

$3.4M

-$47.0K

$1.7M

+22%

+11%

2021

$4.2M

$2.0M

$1.8M

+212%

+25%

2020

$2.7M

$5.9M

$1.3M

+349%

+26%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2024-12	2023-12	2022-12	2021-12
REVENUE	$178.0M	$60.3M	$27.1M	$6.1M
OPERATING INCOME	$-68.8M	$-139.7M	$-164.0M	$-162.2M
NET INCOME	$-70.8M	$-113.9M	$-165.5M	$-158.1M
EPS (DILUTED)	-0.05	-0.09	-0.17	-0.17
OPERATING CASH FLOW	$-73.2M	$-140.9M	$-141.8M	$10.7M
CASH	$91.1M	$144.0M	$108.0M	$149.9M
LONG-TERM DEBT	$50.2M	—	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE